|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The hematopoietic stem cell transplantation market is expected to register a CAGR of 6.2% over the forecast period.
The outbreak of the COVID-19 pandemic has pushed the healthcare industry into action, with a race to develop both therapeutic and diagnostic devices. Exponentially increasing cases of the coronavirus globally are leading to the need for the development of novel treatments, with several clinical trials underway. Meanwhile, the overall healthcare industry was highly focused on developing vaccines and drugs, which can also be applied in the diagnosis and treatment of COVID-19, increasing the rate of clinical trials to a great extent. The market witnessed slow growth during the pandemic as the treatment of leukemia was delayed in many countries. For instance, according to the study titled, "COVID-19 infection in patients with acute leukemia; Istanbul experience" published in August 2021, the proper management of acute leukemia is necessary as it may lead to death if it is not treated promptly. This became a challenge during the pandemic. In addition, several guidelines were also published to decrease mortality in acute leukemia patients. Moreover, it also stated that the management of leukemia patients with COVID-19 infection was also very challenging during the pandemic. Hematopoietic stem cell transplantation is one of the effective treatments for leukemia. Therefore, such instances indicate that the market witnessed a slow growth rate during the pandemic.
The increasing incidence of leukemia and lymphoproliferative disorders and increasing R&D activities by biotechnology companies are the major drivers for the market. According to the data published by the Leukemia & Lymphoma Society (LLS) in 2021, around 61,090 people were estimated to be diagnosed with leukemia 2021. In addition, it also reported that around 397,501 people were living with or in remission from leukemia in the United States in 2021. Furthermore, it also stated that around every 3 minutes, one person in the United States was diagnosed with leukemia, lymphoma, or myeloma. Similarly, according to the study titled, "Rates and trends of childhood acute lymphoblastic leukemia: an epidemiology study" published in April 2021, acute lymphoblastic leukemia (ALL) is the most common cancer in childhood, with a prevalence of up to 25.0% of cancers in children who are under the age of 15 years. Hence, these factors are expected to drive the market growth.
However, the high cost associated with the transplantation procedures may likely hinder the market growth over the forecast period.
Scope of the Report
As per the scope of the report, hematopoietic stem cell transplantation is a procedure that involves the intravenous infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. The hematopoietic stem cell transplantation market is segmented by Type (Autologous Transplant and Allogenic Transplant), Indication (Leukemia, Lymphoproliferative Disorders, and Non-Malignant Disorders), Application (Bone Marrow Transplant, Peripheral Blood Stem Cell Transplant, and Cord Blood Transplant), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
|Bone Marrow Transplant|
|Peripheral Blood Stem Cell Transplant|
|Cord Blood Transplant|
Key Market Trends
Bone Marrow Transplant Segment is Expected to Witness Growth Over the Forecast Period
A bone marrow transplant is a procedure in which healthy blood-forming stem cells are injected into the body to replace bone marrow that does not produce enough healthy blood cells. A bone marrow transplant is also called a stem cell transplant. The bone marrow transplant involves the administration of healthy hematopoietic stem cells in patients with dysfunctional or depleted bone marrow. This procedure is used to treat certain types of cancers, such as leukemia, myeloma, lymphoma, and other blood and immune system diseases that affect the bone marrow.
The increasing research and development activities are expected to boost segment growth over the forecast period. For instance, in Oct 2020, Gamida Cell Ltd., announced that the Phase 3 study of omidubicel, investigational advanced cell therapy in development is a potentially life-saving treatment option for patients in need of bone marrow transplant and also met all three of its secondary endpoints. In addition, increasing positive activities by public and private sectors toward bone marrow transplants are also anticipated to surge segment growth. For instance, in September 2022, QUINT founders donated around USD 16.0 million to establish the QUINT bone marrow transplant centre in Dubai. In addition, high efficacy and advantages of bone marrow transplant in treating acute myeloid leukemia is also driving the segment growth. For instance, as per the study published by the University of California San Francisco in 2021, allogeneic transplantation using stem cells or bone marrow from a tissue-matched brother or sister or unrelated donor produces cure rates of approximately 50.0% to 60.0% in patients with intermediate-risk of acute myeloid leukemia.
Therefore such instances indicate considerable growth of the segment over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Hematopoietic Stem Cell Transplantation Market Over the Forecast Period
North America is expected to dominate the overall hematopoietic stem cell transplantation market, over the forecast period. The growth is due to factors such as the rising cases of leukemia, and increasing investment in research and development by public and private sectors are the major drivers for the market in the North America region. For instance, as per the data published by the Canadian Cancer Society in May 2022, 6,700 Canadians is expected to be diagnosed with leukemia in 2022. It also reported that 4,000 men will be diagnosed with leukemia and around 2,700 women will be diagnosed with leukemia and 1,300 will die from it. Stem cell transplants help with leukemia by allowing the body to replace damaged blood cells with healthy ones. Hematopoietic stem cells help with leukemia by allowing the body to replace damaged blood cells with healthy ones. Stem cells can turn into many other types of cells. Therefore, increasing cases of leukemia are expected to propel the demand for hematopoietic stem cell transplantation, thereby propelling market growth over the forecast period.
Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing United States are some of the factors driving the growth of the hematopoietic stem cell transplantation market in the country. For instance, according to the data published by the Leukemia and Lymphoma Society's facts and Statistics, around 90,390 people in the United States were expected to be diagnosed with lymphoma in 2021 (8,830 Hodgkin Lymphoma cases of and 81,560 cases of Non-Hodgkin Lymphoma).
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.
To understand geography trends, Download Sample Report
The hematopoietic stem cell transplantation market is consolidated and consists of a few major players, that dominate the market. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Merck KGaA, Talaris Therapeutics, Lonza Group, STEMCELL Technologies, Inc, Pluristem Therapeutics, Inc., and ScienCell Research Laboratories, Inc, among others.
STEMCELL Technologies, Inc.
Pluristem Therapeutics, Inc.
ScienCell Research Laboratories, Inc.
- In May 2022, Priothera received the United States Food and Drug Administration clearance of investigational new drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).
- In December 2021, the United States Food and Drug Administration approved the treatment to prevent acute graft-versus-host disease (GVHD) in patients of 2 years of age or older receiving a hematopoietic stem cell transplant from a matched or single-HLA-mismatched unrelated donor.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Leukemia and Lymphoproliferative Disorders
4.2.2 Increasing R&D Activities by Biotechnology Companies
4.3 Market Restraints
4.3.1 High Cost Associated with the Transplantation Procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Type
5.1.1 Autologous Transplant
5.1.2 Allogenic Transplant
5.2 By Indication
5.2.2 Lymphoproliferative Disorders
5.2.3 Non-Malignant Disorders
5.3 By Application
5.3.1 Bone Marrow Transplant
5.3.2 Peripheral Blood Stem Cell Transplant
5.3.3 Cord Blood Transplant
5.4.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.4.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Talaris Therapeutics
6.1.2 Thermo Fisher Scientific
6.1.3 STEMCELL Technologies, Inc.
6.1.4 Pluristem Therapeutics, Inc.
6.1.5 Merck KGaA
6.1.6 Lonza Group
6.1.7 Sartorius CellGenix GmbH (CellGenix GmbH)
6.1.8 ScienCell Research Laboratories, Inc.
6.1.9 ThermoGenesis Holdings, Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Hematopoietic Stem Cell Transplantation Market market is studied from 2019 - 2027.
What is the growth rate of Global Hematopoietic Stem Cell Transplantation Market?
The Global Hematopoietic Stem Cell Transplantation Market is growing at a CAGR of 6.2% over the next 5 years.
Which region has highest growth rate in Global Hematopoietic Stem Cell Transplantation Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Hematopoietic Stem Cell Transplantation Market?
North America holds highest share in 2021.
Who are the key players in Global Hematopoietic Stem Cell Transplantation Market?
STEMCELL Technologies, Inc., Pluristem Therapeutics, Inc. , Merck KGaA, ScienCell Research Laboratories, Inc. , Lonza Group are the major companies operating in Global Hematopoietic Stem Cell Transplantation Market.